Asia Pacific Insulin Market Size To Reach $7.09 Billion By 2030

Asia Pacific Insulin Market Growth & Trends

The Asia Pacific insulin market size is expected to reach USD 7.09 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new study by Grand View Research, Inc. Growing regional prevalence of diabetes, increasing market penetration rates of modern insulin products in emerging markets such as India and China is expected to drive market growth during the forecast period. Furthermore, patent expiration of key products such as Lantus is expected to trigger the manufacturing of biosimilars from local manufacturers such as Biocon.

Long-acting analog dominated the overall market in terms of revenue share in 2013, with revenue estimated at USD 2,051.9 million. High prices coupled with relatively higher efficacies exhibited by these products account for its large share. Rapid-acting analogs followed the long-acting segment in 2013 accounting for a revenue share of over 25.0% on account of their high market penetration rates in developed markets such as Australia and Japan.

 Request a free sample copy or view report summary: Asia Pacific Insulin Market Report

Asia Pacific Insulin Market Report Highlights

• The long-acting segment dominated the regional market in 2023 with a share of 53.07%. This growth is primarily driven by the rising need for long-acting insulin due to applications in Type I diabetes and II diabetes across the region and the globe.

• In 2023, the insulin analog segment held the largest revenue share of 88.6%. Insulin analog is created to mirror the pancreas' natural insulin release pattern, effectively regulating the body's blood sugar levels.

• The market share for type I diabetes in the Asia Pacific region reached 79.03% in 2023. Type I diabetes application is further projected to experience substantial expansion as a result of the increasing incidence of type I diabetes in children and teenagers.

• The retail & specialty pharmacies segment led the market and accounted for a revenue share of 89.9% in 2023. Looking toward the future, these pharmacies are projected to experience substantial growth.

Asia Pacific Insulin Market Segmentation

Grand View Research has segmented Asia Pacific insulin market report based on product, type, application, distribution, and country:

Asia Pacific Insulin Type Outlook (Revenue, USD Million, 2018 - 2030)

• Insulin Analog

• Human Insulin

Asia Pacific Insulin Application Outlook (Revenue, USD Million, 2018 - 2030)

• Type1 Diabetes

• Type II Diabetes

Asia Pacific Insulin Product Outlook (Revenue, USD Million, 2018 - 2030)

• Rapid-acting Insulin

• Long-acting Insulin

• Combination Insulin

• Biosimilar

• Other Products

Asia Pacific Insulin Distribution Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail & Specialty Pharmacies

• Other Distribution Channel

Asia Pacific Insulin Country Outlook (Revenue, USD Million, 2018 - 2030)

• Japan

• China

• India

• South Korea

• Australia

• Singapore

• Philippines

• Malaysia

• Thailand

• Rest of Asia Pacific

List of Key Players of Asia Pacific Insulin Market

• Novo Nordisk A/S

• Eli Lilly and Company

• Sanofi

• Biocon

• Boehringer Ingelheim International GmbH

• The United Laboratories International Holdings Ltd.

• Tonghua Dongbao Pharmaceutical Co. Ltd.

• Gan & Lee Pharmaceuticals